A newly developed risk score could play a critical role in predicting the likelihood of pancreatic cancer recurrence in patients, offering a more tailored approach to post-surgery care. According to researchers, this breakthrough could significantly improve how survivors are monitored, specifically those whose tumors have been surgically removed and have not spread to the lymph nodes.
The study, published in JAMA Surgery on Wednesday, highlights how the score is particularly useful for patients with pancreatic neuroendocrine tumors (PNETs), a rare and typically less aggressive form of pancreatic cancer. For individuals whose cancer has not extended beyond the pancreas to nearby lymph nodes or organs, the five-year survival rate is approximately 91%, post-surgery.
However, recent data from five major hospitals suggest that around 10% of these patients may still experience cancer recurrence, most often in the liver. This was the core finding of the study, prompting the researchers to create a 13-point risk score. Senior researcher Dr. Cristina Ferrone, who is also the chair of surgery at Cedars-Sinai Medical Center in Los Angeles, emphasized the significance of this new tool in identifying patients who are at a higher risk of recurrence—patients who might have been overlooked under previous assessment guidelines.
“The ability to pinpoint patients who are at a greater risk for cancer recurrence allows us to focus on more individualized care, moving away from the traditional ‘one-size-fits-all’ approach,” Ferrone stated. “This research offers an opportunity to transform post-treatment monitoring and improve long-term patient outcomes.”
The risk score is based on four critical factors that contribute to the likelihood of recurrence: male sex, tumor size of 3 cm or larger, a cancer grade of 2 or higher, and invasion of cancer cells into the bloodstream or lymphatic fluid. By applying these factors, doctors can categorize patients into low-, moderate-, and high-risk groups, guiding more personalized surveillance strategies.
The introduction of this risk score comes at a crucial time, as current medical guidelines have failed to provide a nuanced approach to surveillance, often treating all patients the same. “This new score fills a major gap in clinical practice,” Ferrone said, “and has the potential to shape future guidelines for pancreatic cancer care, offering more cost-effective and tailored strategies.”
As more studies are likely to follow, the hope is that these findings will spur improvements in care protocols, ensuring that every patient receives the attention suited to their individual risk of recurrence.
Related topics:
